Scott Thomas Smith
Known title: EVP & Chief Financial OfficerCIK: 0001965550
Scott Thomas Smith's purchase track record
Scott Thomas Smith has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/29/2026 | ASND | $78K | +10.7% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ASND | ▲ Buy | Open Market | 100 | $22K | 6/2/2026 | View on chart |
| ASND | ▲ Buy | Open Market | 250 | $56K | 5/29/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Ascendis Pharma signs BioMarin license deal, ends litigation
Ascendis Pharma has reached a licensing agreement with BioMarin for its TransCon Cnp, Navepegritide, and Yuviwel products. Under the deal, Ascendis will pay royalties on sales in the U.S. and Europe until May 2030, and all pending legal disputes between the two companies have been dismissed. This resolution removes a significant legal uncertainty for the stock, which is currently trading near its 52-week low.
Ascendis Pharma signs BioMarin license deal, ends litigation. Ascendis Pharma has reached a licensing agreement with BioMarin for its TransCon Cnp, Navepegritide, and Yuviwel products. Under the deal, Ascendis will pay royalties on sales in the U.S. and Europe until May 2030, and all pending legal disputes between the two companies have been dismissed. This resolution removes a significant legal uncertainty for the stock, which is currently trading near its 52-week low.